Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper
Nicolò Matteo Luca Battisti(Royal Marsden NHS Foundation Trust), Alistair Ring(National Health Service), Gábor Liposits(Regionshospitalet Herning), Enrique Soto‐Pérez‐de‐Celis(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Mina S. Sedrak(University of California, Los Angeles), Nienke A. de Glas(Leiden University Medical Center), Kah Poh Loh(University of Pavia), Ines B. Menjak, Jessica L. Krok‐Schoen(The Ohio State University)
Cited by 61
Related Papers
Mechanisms of tamoxifen resistance
|Endocrine Related Cancer|2004|652
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
|JAMA Oncology|2019|425
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
|The Lancet Oncology|2020|351
Inflammation Is an Independent Risk Factor for Colonic Neoplasia in Patients With Ulcerative Colitis: A Case–Control Study
|Clinical Gastroenterology and Hepatology|2013|292